Global Acute Lymphocytic/Lymphoblastic leukemia Market 2015-2019

2015-11-11
Price :
Published : Nov-2015
No. of Pages : 65

Global Acute Lymphocytic Leukemia Market 2015-2019

Covering: An in-depth study of the acute lymphocytic leukemia market and segmentation by route of administration (oral and parenteral), by type of molecules (biologics and small molecules), and by geography (the Americas, EMEA, and APAC). The report also presents a detailed analysis of the top companies operating in the market, including Amgen, Bristol-Myers Squibb, and Novartis.

Market landscape of acute lymphocytic leukemia

Acute lymphocytic leukemia or acute lymphoblastic leukemia, is a malignancy of the blood cells that affects the lymphoblasts or leukemic blasts, which witnesses an uncontrolled cell division. The main symptoms a patient exhibits are weakness, tiredness, dizziness, fever, shortness of breath, frequent infections, bruising, and bleeding.

Currently, the disease cannot be cured completely but the risk can be reduced by administering medication.

The market research analysts expect the global acute lymphocytic leukemia market to grow at a steady rate and post a CAGR of over 4% during the forecast period. One of the major factors contributing to the growth of the market is the provision for orphan drugs. For instance, in the US, orphan designation for a drug means incentives like tax credits for qualified clinical testing, exemption from prescription drug user fees unless indicated for additional non-orphan indications, and market exclusivity for seven years.

Segmentation of the acute lymphocytic leukemia market by route of administration

  • Oral
  • Parenteral

Many medications are administered through the oral route to guarantee a systemic effect. The oral route is a sub-division of enteral administration and is considered to be one of the safest and most preferred routes of drug administration.

Geographical segmentation of the acute lymphocytic leukemia market

  • Americas
  • APAC
  • EMEA

With a share of over 49%, the Americas dominated the acute lymphocytic leukemia market, with the US being the major revenue contributor. The Americas is closely followed by the EMEA and the APAC region and the market is expected to follow a similar trend during the forecast period.

Competitive landscape and key vendors

The acute lymphocytic leukemia market is marked by the presence of both global and local drug manufacturers with varied product portfolios containing generic and off- label drugs as well as branded therapies. Besides, the high level of unmet medical need is expected to give a platform to the vendors to develop products to cater to relevant areas and enhance their market shares.

Primary vendors in this market are -

  • Amgen
  • Bristol-Myers Squibb
  • Novartis

Other prominent vendors included in this report are Ariad, Arno Therapeutics, Baxter, Boehringer Ingelheim, ERYTECH Pharma, Fate Therapeutics, Jazz Pharmaceuticals, Orphan Europe, Otsuka, Ono Pharmaceuticals, Onconova Therapeutics, Pfizer, Regeneron Pharmaceuticals, Sanofi, and Sigma-Tau Pharmaceuticals.

Key questions answered in the report include

  • What will the market size and the growth rate be in 2019?
  • What are the key factors driving the global acute lymphocytic leukemia market?
  • What are the key market trends impacting the growth of the global acute lymphocytic leukemia market?
  • What are the challenges to market growth?
  • Who are the key vendors in the global acute lymphocytic leukemia market?
  • What are the market opportunities and threats faced by the vendors in the global acute lymphocytic leukemia market?
  • What are the trending factors influencing the market shares of the Americas, EMEA, and APAC?
  • What are the key outcomes of the five forces analysis of the global acute lymphocytic leukemia market?
Filed in: Pharmaceutical, Therapeutics
Publisher : Technavio
More Reports
Title Price Buy Now

ForeSights: Digiceuticals

ForeSights: Digiceuticals Summary Digiceuticals are computer software, smartphones, digital services, and so on with the potential to improve health outcomes as much as drugs can. Digiceuticals reside at the intersection of medicine and digital health technology and have the potential to increase medication compliance and enhance focus on patient behavior modification. Digiceuticals are a promising new development in healthcare that use technology to leverage and improve the effectiveness of pharmaceuticals, even replacing them in some cases. Scope - Technology is often used to create pharmaceuticals, but is rarely used to improve the efficacy of drugs already prescribed. The latter is at the core of the digiceuticals concept. - Digiceuticals have the potential to increase medication ......
$495

PharmSource – Contract Dose Manufacturing Industry by the Numbers: Composition, Size, Market Share and Outlook – 2017 Edition

PharmSource - Contract Dose Manufacturing Industry by the Numbers: Composition, Size, Market Share and Outlook - 2017 Edition Summary Contract Dose Manufacturing universe, for purposes of this report, includes companies that actively promote themselves as contract manufacturers (CMOs) that produce a client's formulation for pharmaceuticals supplied to the highly-regulated markets in North America, Europe and Japan. Contract dose manufacturing universe includes 282 companies headquar¬tered primarily in North America, Europe, Japan and India. One hundred and eighty-one companies (64%) pursue contract manufacturing as their primary business, while the remainder (36%) contract manufacture in facilities where they produce their own products. Size of the dose CMO market in 2016 was $19.3 bil......
$2995

Partnerships, Licensing, Investments and M&A Deals and Trends for May 2017 in Pharmaceuticals

Partnerships, Licensing, Investments and M&A Deals and Trends for May 2017 in Pharmaceuticals Summary GlobalData's "Partnerships, Licensing, Investments and M&A Deals and Trends for May 2017 in Pharmaceuticals", report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in May 2017. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides infor......
$1000

EpiCast Report: Type 2 Diabetes – Epidemiology Forecast to 2026

EpiCast Report: Type 2 Diabetes - Epidemiology Forecast to 2026 Summary Type 2 diabetes (T2D), formerly known as non-insulin dependent diabetes mellitus or adult-onset diabetes mellitus, is a chronic disorder of glucose equilibrium that results from the body's inability to make use of available insulin along with relative insulin deficiency (WHO, 2016a). T2D constitutes approximately 90-95% of all diabetes cases around the world while, type 1 diabetes (T1D) and gestational diabetes make up the remaining 5-10% of the cases (CDC, 2011; CDC, 2014b; IDF, 2014). The prevalence of diabetes is expected to grow rapidly as it is associated with aging populations, increasing urbanization, economic development, and the increase in the prevalence of risk factors like obesity, unhealthy dietary habi......
$3995

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape – Canada

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Canada Summary Canada is a mature healthcare market, with a strong focus on pharma R&D and a high level of total healthcare expenditure that is 11% of its Gross Domestic Product (GDP). The increasing elderly population and its associated disease burden are expected to drive the growth of the pharmaceutical market, while government initiatives to reduce healthcare expenditure may limit growth. The value of the Canadian pharmaceutical market increased from US$19.6 Billion in 2009 to US$22.6 Billion in 2016, at a Compound Annual Growth Rate (CAGR) of 2%. The market value is expected to reach US$25 Billion in 2021. In 2016, the value of the generic pharmaceutical market was US$6.16 Billion. In 2016, generic drugs accounted f......
$1995

Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals – Q1 2017

Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q1 2017 Summary GlobalData's "Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q1 2017", report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in Q1 2017. The report portrays detailed comparative data on the number of deals and their value in the last five quarters, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides informati......
$1500

EpiCast Report: Hemophilia – Epidemiology Forecast to 2026

EpiCast Report: Hemophilia - Epidemiology Forecast to 2026 Summary Hemophilia is an X-linked hereditary bleeding disorder, characterized by impaired blood coagulation as a result of deficiencies in the production or function of coagulation factor VIII (FVIII) in hemophilia A or factor IX (FIX) in hemophilia B (Bolton-Maggs and Pasi, 2003). Because of the deficiency of coagulation factor, hemophilia patients have a tendency for bleeding in joints, muscles, soft tissues, and within mucous membranes, which can be either spontaneous or due to internal or external trauma, depending on the severity of the disease (CDC, 2017b; Mayo Clinic, 2014). In the 7MM, epidemiologists forecast an increase in the diagnosed prevalent cases of hemophilia A and hemophilia B, from 51,627 diagnosed prevalent c......
$3995

EpiCast Report: Chronic Obstructive Pulmonary Disease – Epidemiology Forecasts to 2025

EpiCast Report: Chronic Obstructive Pulmonary Disease - Epidemiology Forecasts to 2025 Summary Chronic obstructive pulmonary disease (COPD), also known as chronic obstructive lung disease (COLD), is a condition characterized by difficulty in breathing, shortness of breath, wheezing, chest tightness, and other respiratory symptoms that progress over time. The disease is often caused by smoking; however, long-term exposure to other lung irritants, such as pollution, smoke from vehicle emissions and power stations, chemical fumes, and dust, can also lead to the development of COPD (NHLBI, 2013). In the 8MM, epidemiologists forecast that the total prevalent cases of COPD will increase from 65,991,432 cases in 2015 to 76,066,482 cases in 2025 at an Annual Growth Rate (AGR) of 1.53%. The US w......
$3995

EpiCast Report: Acute Myeloid Leukemia – Epidemiology Forecast to 2026

EpiCast Report: Acute Myeloid Leukemia - Epidemiology Forecast to 2026 Summary Acute Myeloid Leukemia (AML), also known as myelogenous leukemia, acute myelocytic leukemia, or acute nonlymphocytic leukemia, is a rare cancer that accounts for a disproportionally high number of cancer-related deaths. The disease is more common in the elderly, and is relatively more common in men than in women (ACS, 2013; O'Donnell et al., 2012). AML starts in the bone marrow, where the developing white blood cells-including granulocytes and monocytes-mature abnormally, grow uncontrollably, and quickly overcrowd the blood, spreading into other parts of the body, including the lymph nodes, liver, and brain (ACS, 2013; ASCO, 2012). The symptoms are nonspecific and may include weight loss, fatigue, fever, p......
$3995

EpiCast Report: Heart Failure – Epidemiology Forecasts to 2026

EpiCast Report: Heart Failure - Epidemiology Forecasts to 2026 Summary Heart failure (HF), also referred to as congestive cardiac failure, is a heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic needs of the body (AHA, 2015a). HF commonly occurs in people older than 50 years of age, and severity increases progressively with age (Mosterd and Hoes, 2007). The symptoms can develop quickly, such as in acute HF, at which time the patient needs to be hospitalized. However, in chronic HF (CHF), the symptoms develop gradually (NHS, 2014). Eventually, without the heart's pumping action to deliver oxygen and nutrient-rich blood to the cells, fatigue, shortness of breath, and coughing results. Even everyday activities such as walking, climbing s......
$3995